The most commonly reported side effects of teclistamab include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and plasma cell myeloma, based on 3,157 FDA adverse event reports from 2021 to 2025. 4.2% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for teclistamab.
These are voluntary reports and do not establish that teclistamab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside teclistamab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
30.4% of teclistamab adverse event reports involve female patients and 36.4% involve male patients. The largest age group is elderly at 64%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking teclistamab when the adverse event was reported.
Showing 15 of 37 indications
Teclistamab is sold under the brand name Tecvayli.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.